Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers.
To shed light on the metabolic changes in glioma following therapy, uptake changes among 18F-fluoro-2'-deoxyuridine (18FUdR), 14C-thymidine (dThd), 14C-methionine (Met) and 3H-deoxyglucose (DG) in glioma model after chemotherapy were studied, as a means for interpreting clinical PET results, together with the changes in the bromodeoxyuridine (BUdR) labeling index. 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(-2chloroethyl)-3-nitro sourea hydrochloride (ACNU) was administered intraperitoneally in the tumor-bearing rats and uptake of the tracers or BUdR labeling index in tumor tissue were measured. The metabolic response following chemotherapy was a sharp fall immediately for 14C-dThd and 18FUdR and a moderate fall for 14C-Met whereas there was a fall in 3H-DG from 1 week after chemotherapy. The changes of BUdR labeling index paralleled that in the uptake for dThd and FUdR. These result indicate that PET scans using a variety of tracers in conjunction could be used for clinical diagnosis and evaluation of therapy in glioma cases. 18FUdR is a promising tracer of nucleic acid metabolism to evaluate the proliferative potential of brain gliomas.
Sato
K
K
Division of Neurosurgery, Tohoku University School of Medicine, Japan.
Kameyama
M
M
Ishiwata
K
K
Katakura
R
R
Yoshimoto
T
T
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002250:Carbon Radioisotopes; D004261:DNA Replication / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000096:biosynthesis*; D003847:Deoxyglucose / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005467:Floxuridine / Q000493:pharmacokinetics; D005462:Fluorine Radioisotopes; D005910:Glioma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D006119:Groin; D008297:Male; D008715:Methionine / Q000493:pharmacokinetics; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009368:Neoplasm Transplantation; D015376:Nimustine / Q000494:pharmacology* / Q000627:therapeutic use; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D051381:Rats; D017208:Rats, Wistar; D015996:Survival Rate; D013936:Thymidine / Q000493:pharmacokinetics; D014055:Tomography, Emission-Computed; D014316:Tritium
D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D005462:Fluorine Radioisotopes; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm; D005467:Floxuridine; D015376:Nimustine; D014316:Tritium; D003847:Deoxyglucose; D008715:Methionine; D013936:Thymidine